The researchers suggest clinicians might tailor their approach to account for Asian Americans' younger average age when they ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that is thought to be an autoimmune disorder where ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

In addition to OCREVUS, Roche has a diverse and promising pipeline of formulations and targets, such as Brainshuttle™ CD20 ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in the disease.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...